This morning I read an IMPORTANT Science Daily article on how the adverse effects, tolerability, and toxicities of conventional treatments for blood cancers (including myeloma, of course) have not been reported/disclosed as well as they should have been, to put it mildly. See: goo.gl/ou9CNg
Well, this may change soon enough: a new commission set up by The Lancet Haematology has been looking into these adverse effects and toxicities, considering in particular the long-term, chronic effects that don’t go away even after the completion of treatment, such as neuropathy, which can be crippling.
Quality of life has always been a big concern of mine, and I always look for adverse effects and toxicities whenever I read studies about patients and conventional treatments. Very rarely, however, are adverse effects mentioned…The first study that comes to mind is the Spanish SMM patient-chemo study, where there was no information on how the early treatment of SMM patients affected their daily lives. And yet their lives must have been affected, at least in some ways…
Excerpt from the SD article: “In particular, the toxicity over time and tolerability to the patient of new chronic or continuously administered therapies are not well defined, and are poorly captured by existing reporting mechanisms.”
Well, the important thing is that FINALLY (about time!!!) there is a commission looking into this lesser-disclosed (to say the least) part of conventional treatments. This is very good news.
We, the patients, need to be INFORMED about any and all potential problems, both short-term and long-term…
Or, at least, that is MY opinion! As usual!!! 🙂
